UGT1A1 and liver disorder: Filopanti et al. showed that in acromegalic patients treated with PEGv, multitherapies and previous episodes of liver disease were associated with increased risk of hepatotoxicity; however, they did not find any increased risk of liver toxicity in Italian patients with UGT1A1⁎28 polymorphism [15].